{"count": 11, "results": [{"_id": "37456496", "pmid": 37456496, "pmcid": "PMC10349656", "title": "Safety and Efficacy of Ondansetron and Simvastatin as Potential Adjunctive Treatment for Patients With Schizophrenia: A Systematic Review of Randomized Controlled Trials", "journal": "Cureus", "authors": ["Khan KI", "Al Shouli R", "Allakky A", "Ferguson AA", "Khan AI", "Abuzainah B", "Gutlapalli SD", "Chaudhuri D", "Hamid P"], "date": "2023-06-15T00:00:00Z", "doi": "10.7759/cureus.40474", "meta_date_publication": "2023 Jun", "meta_volume": "15", "meta_issue": "6", "meta_pages": "e40474", "score": 50279.43, "text_hl": "Safety and Efficacy of @CHEMICAL_Ondansetron @CHEMICAL_MESH:D017294 @@@Ondansetron@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ as Potential Adjunctive Treatment for @SPECIES_9606 @@@Patients@@@ With @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@Schizophrenia@@@: A Systematic Review of Randomized Controlled Trials", "citations": {"NLM": "Khan KI, Al Shouli R, Allakky A, Ferguson AA, Khan AI, Abuzainah B, Gutlapalli SD, Chaudhuri D, Hamid P. Safety and Efficacy of Ondansetron and Simvastatin as Potential Adjunctive Treatment for Patients With Schizophrenia: A Systematic Review of Randomized Controlled Trials Cureus. 2023 Jun;15(6):e40474. PMID: 37456496", "BibTeX": "@article{37456496, title={Safety and Efficacy of Ondansetron and Simvastatin as Potential Adjunctive Treatment for Patients With Schizophrenia: A Systematic Review of Randomized Controlled Trials}, author={Khan KI and Al Shouli R and Allakky A and Ferguson AA and Khan AI and Abuzainah B and Gutlapalli SD and Chaudhuri D and Hamid P}, journal={Cureus}, volume={15}, number={6}, pages={e40474}}"}}, {"_id": "38377869", "pmid": 38377869, "title": "Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia.", "journal": "Schizophr Res", "authors": ["Zaki JK", "Lago SG", "Spadaro B", "Rustogi N", "Gangadin SS", "Benacek J", "Drexhage HA", "de Witte LD", "Kahn RS", "Sommer IEC", "Bahn S", "Tomasik J"], "date": "2024-02-19T00:00:00Z", "doi": "10.1016/j.schres.2024.02.011", "meta_date_publication": "2024 Feb 19", "meta_volume": "266", "meta_issue": "", "meta_pages": "66-74", "score": 50271.773, "text_hl": "Exploring peripheral biomarkers of response to @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ supplementation in @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@.", "citations": {"NLM": "Zaki JK, Lago SG, Spadaro B, Rustogi N, Gangadin SS, Benacek J, Drexhage HA, de Witte LD, Kahn RS, Sommer IEC, Bahn S, Tomasik J. Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia. Schizophr Res. 2024 Feb 19;266():66-74. PMID: 38377869", "BibTeX": "@article{38377869, title={Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia.}, author={Zaki JK and Lago SG and Spadaro B and Rustogi N and Gangadin SS and Benacek J and Drexhage HA and de Witte LD and Kahn RS and Sommer IEC and Bahn S and Tomasik J}, journal={Schizophr Res}, volume={266}, pages={66-74}}"}}, {"_id": "37373704", "pmid": 37373704, "pmcid": "PMC10299654", "title": "Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia:A Systematic Review", "journal": "J Clin Med", "authors": ["Dróżdż W", "Wiciński M", "Szota AM", "Szambelan M", "Radajewska I", "Popławski I", "Wojciechowski P"], "date": "2023-06-12T00:00:00Z", "doi": "10.3390/jcm12124012", "meta_date_publication": "2023 Jun 12", "meta_volume": "12", "meta_issue": "12", "meta_pages": "", "score": 50262.742, "text_hl": "A combination of antipsychotic medication with @CHEMICAL_Aspirin @CHEMICAL_MESH:D001241 @@@aspirin@@@, @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, @CHEMICAL_Acetylcysteine @CHEMICAL_MESH:D000111 @@@N-acetylcysteine@@@, or @CHEMICAL_Pioglitazone @CHEMICAL_MESH:D000077205 @@@pioglitazone@@@ seems to be effective in the reduction of symptoms of @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@ in adults, but long-term studies are required to confirm this effect.", "citations": {"NLM": "Dróżdż W, Wiciński M, Szota AM, Szambelan M, Radajewska I, Popławski I, Wojciechowski P. Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia:A Systematic Review J Clin Med. 2023 Jun 12;12(12):. PMID: 37373704", "BibTeX": "@article{37373704, title={Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia:A Systematic Review}, author={Dróżdż W and Wiciński M and Szota AM and Szambelan M and Radajewska I and Popławski I and Wojciechowski P}, journal={J Clin Med}, volume={12}, number={12}}"}}, {"_id": "39258162", "pmid": 39258162, "title": "Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.", "journal": "Neuropsychiatr Dis Treat", "authors": ["Chen J", "Yuan Y", "Hu Y", "Liang L"], "date": "2024-09-06T00:00:00Z", "doi": "10.2147/NDT.S480921", "meta_date_publication": "2024", "meta_volume": "20", "meta_issue": "", "meta_pages": "1667-1675", "score": 50259.176, "text_hl": "Lack of Efficacy of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ Adjunctive Therapy for @SPECIES_9606 @@@Patients@@@ with @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@Schizophrenia@@@: A Meta-Analysis of Randomized Controlled Trials.", "citations": {"NLM": "Chen J, Yuan Y, Hu Y, Liang L. Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials. Neuropsychiatr Dis Treat. 2024;20():1667-1675. PMID: 39258162", "BibTeX": "@article{39258162, title={Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.}, author={Chen J and Yuan Y and Hu Y and Liang L}, journal={Neuropsychiatr Dis Treat}, volume={20}, pages={1667-1675}}"}}, {"_id": "34947895", "pmid": 34947895, "pmcid": "PMC8703562", "title": "Update on Statin Treatment in Patients with Neuropsychiatric Disorders", "journal": "Life (Basel)", "authors": ["Avan R", "Sahebnasagh A", "Hashemi J", "Monajati M", "Faramarzi F", "Henney NC", "Montecucco F", "Jamialahmadi T", "Sahebkar A"], "date": "2021-12-08T00:00:00Z", "doi": "10.3390/life11121365", "meta_date_publication": "2021 Dec 8", "meta_volume": "11", "meta_issue": "12", "meta_pages": "", "score": 50258.06, "text_hl": "Tajik-Esmaeeli et al. in a double-blind RCT showed that the use of 40 mg daily @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ for eight weeks could reduce the negative but not positive symptoms of @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@. ", "citations": {"NLM": "Avan R, Sahebnasagh A, Hashemi J, Monajati M, Faramarzi F, Henney NC, Montecucco F, Jamialahmadi T, Sahebkar A. Update on Statin Treatment in Patients with Neuropsychiatric Disorders Life (Basel). 2021 Dec 8;11(12):. PMID: 34947895", "BibTeX": "@article{34947895, title={Update on Statin Treatment in Patients with Neuropsychiatric Disorders}, author={Avan R and Sahebnasagh A and Hashemi J and Monajati M and Faramarzi F and Henney NC and Montecucco F and Jamialahmadi T and Sahebkar A}, journal={Life (Basel)}, volume={11}, number={12}}"}}, {"_id": "37126871", "pmid": 37126871, "title": "A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder.", "journal": "Eur Neuropsychopharmacol", "authors": ["Weiser M", "Levi L", "Park J", "Nastas I", "Matei V", "Davidson M", "Arad I", "Dudkiewicz I", "Davis JM"], "date": "2023-04-29T00:00:00Z", "doi": "10.1016/j.euroneuro.2023.04.007", "meta_date_publication": "2023 Apr 29", "meta_volume": "73", "meta_issue": "", "meta_pages": "65-74", "score": 50256.52, "text_hl": "However, the meta-analysis of all studies of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ for @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@ indicates further research on this topic.", "citations": {"NLM": "Weiser M, Levi L, Park J, Nastas I, Matei V, Davidson M, Arad I, Dudkiewicz I, Davis JM. A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2023 Apr 29;73():65-74. PMID: 37126871", "BibTeX": "@article{37126871, title={A randomized controlled trial of add-on naproxen, simvastatin and their combination for the treatment of schizophrenia or schizoaffective disorder.}, author={Weiser M and Levi L and Park J and Nastas I and Matei V and Davidson M and Arad I and Dudkiewicz I and Davis JM}, journal={Eur Neuropsychopharmacol}, volume={73}, pages={65-74}}"}}, {"_id": "39233601", "pmid": 39233601, "title": "Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 x 2 factorial design, randomised controlled comparison with simvastatin.", "journal": "J Psychopharmacol", "authors": ["Chaudhry IB", "Husain MO", "Khoso AB", "Kiran T", "Husain MI", "Qurashi I", "Rahman RU", "Mehmood N", "Drake R", "Husain N", "Deakin B"], "date": "2024-09-05T00:00:00Z", "doi": "10.1177/02698811241267836", "meta_date_publication": "2024 Sep 5", "meta_volume": "", "meta_issue": "", "meta_pages": "2698811241267836", "score": 50252.676, "text_hl": "In total, 303 people with stable treated @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@ aged 18-65 were randomly allocated to add-on @CHEMICAL_Ondansetron @CHEMICAL_MESH:D017294 @@@ondansetron@@@, @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@, both or neither. ", "citations": {"NLM": "Chaudhry IB, Husain MO, Khoso AB, Kiran T, Husain MI, Qurashi I, Rahman RU, Mehmood N, Drake R, Husain N, Deakin B. Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 x 2 factorial design, randomised controlled comparison with simvastatin. J Psychopharmacol. 2024 Sep 5;():2698811241267836. PMID: 39233601", "BibTeX": "@article{39233601, title={Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 x 2 factorial design, randomised controlled comparison with simvastatin.}, author={Chaudhry IB and Husain MO and Khoso AB and Kiran T and Husain MI and Qurashi I and Rahman RU and Mehmood N and Drake R and Husain N and Deakin B}, journal={J Psychopharmacol}, pages={2698811241267836}}"}}, {"_id": "30461427", "pmid": 30461427, "title": "Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6.", "journal": "Int Clin Psychopharmacol", "authors": ["Francesconi LP", "Victorino AT", "Salah IA", "Cordova VHS", "Dias da Rosa E", "Oliveira L", "Jacobus RVM", "Belmonte-de-Abreu PS", "Ceresér KM"], "date": "2019-03-01T00:00:00Z", "doi": "10.1097/YIC.0000000000000241", "meta_date_publication": "2019 Mar", "meta_volume": "34", "meta_issue": "2", "meta_pages": "84-88", "score": 50059.176, "text_hl": "Proinflammatory and anti-@DISEASE_Inflammation @DISEASE_MESH:D007249 @@@inflammatory@@@ biomarkers in @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@ and influence of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ on the @GENE_IL6 @GENE_3569 @@@interleukin-6@@@.", "citations": {"NLM": "Francesconi LP, Victorino AT, Salah IA, Cordova VHS, Dias da Rosa E, Oliveira L, Jacobus RVM, Belmonte-de-Abreu PS, Ceresér KM. Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6. Int Clin Psychopharmacol. 2019 Mar;34(2):84-88. PMID: 30461427", "BibTeX": "@article{30461427, title={Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6.}, author={Francesconi LP and Victorino AT and Salah IA and Cordova VHS and Dias da Rosa E and Oliveira L and Jacobus RVM and Belmonte-de-Abreu PS and Ceresér KM}, journal={Int Clin Psychopharmacol}, volume={34}, number={2}, pages={84-88}}"}}, {"_id": "27941358", "pmid": 27941358, "title": "Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial.", "journal": "Int Clin Psychopharmacol", "authors": ["Tajik-Esmaeeli S", "Moazen-Zadeh E", "Abbasi N", "Shariat SV", "Rezaei F", "Salehi B", "Akhondzadeh S"], "date": "2017-03-01T00:00:00Z", "doi": "10.1097/YIC.0000000000000159", "meta_date_publication": "2017 Mar", "meta_volume": "32", "meta_issue": "2", "meta_pages": "87-94", "score": 50057.938, "text_hl": "@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ adjunct therapy for @DISEASE_Triple_Negative_Breast_Neoplasms @DISEASE_MESH:D064726 @@@negative symptoms@@@ of @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@: a randomized double-blind placebo-controlled trial.", "citations": {"NLM": "Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N, Shariat SV, Rezaei F, Salehi B, Akhondzadeh S. Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial. Int Clin Psychopharmacol. 2017 Mar;32(2):87-94. PMID: 27941358", "BibTeX": "@article{27941358, title={Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial.}, author={Tajik-Esmaeeli S and Moazen-Zadeh E and Abbasi N and Shariat SV and Rezaei F and Salehi B and Akhondzadeh S}, journal={Int Clin Psychopharmacol}, volume={32}, number={2}, pages={87-94}}"}}, {"_id": "23782463", "pmid": 23782463, "pmcid": "PMC3680972", "title": "Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial", "journal": "Trials", "authors": ["Chaudhry IB", "Husain N", "Husain MO", "Hallak J", "Drake R", "Kazmi A", "Rahman Ru", "Hamirani MM", "Kiran T", "Mehmood N", "Stirling J", "Dunn G", "Deakin B"], "date": "2013-04-17T00:00:00Z", "doi": "10.1186/1745-6215-14-101", "meta_date_publication": "2013 Apr 17", "meta_volume": "14", "meta_issue": "", "meta_pages": "101", "score": 50056.477, "text_hl": "@CHEMICAL_Ondansetron @CHEMICAL_MESH:D017294 @@@Ondansetron@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ added to treatment as usual in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Schizophrenia</m> @DISEASE_MESH:D012559 @@@schizophrenia@@@: study protocol for a randomized controlled trial", "citations": {"NLM": "Chaudhry IB, Husain N, Husain MO, Hallak J, Drake R, Kazmi A, Rahman Ru, Hamirani MM, Kiran T, Mehmood N, Stirling J, Dunn G, Deakin B. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial Trials. 2013 Apr 17;14():101. PMID: 23782463", "BibTeX": "@article{23782463, title={Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial}, author={Chaudhry IB and Husain N and Husain MO and Hallak J and Drake R and Kazmi A and Rahman Ru and Hamirani MM and Kiran T and Mehmood N and Stirling J and Dunn G and Deakin B}, journal={Trials}, volume={14}, pages={101}}"}}]}